China Blood Product Industry Report, 2017-2021
  • Apr.2017
  • Hard Copy
  • USD $2,900
  • Pages:172
  • Single User License
    (PDF Unprintable)       
  • USD $2,700
  • Code: ZLC048
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,100
  • Hard Copy + Single User License
  • USD $3,100
      

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 2015, estimated to reach RMB23.8 billion throughout the year, up 16.7% from 2015.

China’s blood product industry will develop at full speed boosted by downstream demand, accompanied by a steady rise in the number of plasma stations and consolidated profit margin improvement of plasma. The market size is expected to hit RMB47.5 billion in 2021.

Main features of blood product industry in China 2016 are shown as below:

1. As plasma supply increases, supply-demand balance can be seen in 2025
China’s plasma collection volume has been increasing over recent years driven by blood product price deregulation and accelerated establishment of new plasma stations. In 2016, 6,964 tons of plasma was collected in China, up 19.8% year on year. Despite continuous growth, plasma collection volume still cannot meet the ever-increasing market demand. In the future, China will see plasma collection volume shooting up propelled by a growing number of plasma collection stations and is expected to achieve balance between plasma supply and demand in 2025.

2. A steady increase in lot release volume of main products
So far, Chinese blood products are still dominated by human albumin and human immunoglobulin for intravenous injection, which take an over 70% blood product market share. In 2016, human albumin and human immunoglobulin (pH4) for intravenous injection registered respective lot release volumes of 39.31 million bottles (10g/bottle) and 10.89 million bottles (2.5g/bottle), up 17.8% and 27.4% respectively year on year.

In addition, lot release volumes of domestic blood products in short supply such as blood coagulation factor VIII, human immunoglobulin and human prothrombin complex also witnessed substantial growth in 2016, respectively 38.0%, 143.8% and 20%.

3. R&D efforts intensified for new products; comprehensive utilization of plasma to be raised
At present, Chinese blood product enterprises can separate a maximum of 11 varieties of blood products from the plasma, 3-4 varieties for general firms, indicating an extremely low rate of comprehensive utilization of plasmas. To solve the problem, Chinese blood product enterprises are accelerating the development of new products, hoping to improve comprehensive utilization of plasma.

Blood coagulation factor VIII, for example, Guizhou Taibang Biological Products Co., Ltd., Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Zhenxing Biopharmaceutical & Chemical Co., Ltd., Wuhan Zhongyuan Ruide Biological Products Co., Ltd. etc. are actively conducting clinical trials of blood coagulation factor VIII and expected to achieve mass production in next two years.

4 Plasma-oriented pattern continues
Blood product industry relies heavily on plasma materials – the number of plasma stations directly influences plasma collection volume, which then affects raw material supply of blood product enterprises. Therefore, the number of plasma stations and plasma collection volume determine corporate position in industry.

There are over 30 blood product manufacturing enterprises in China, but only more than 20 are able to maintain normal production. Among them, Hualan Biological Engineering,Inc., Shanghai RAAS Blood Products Co., Ltd. and China Biologic Products, Inc. boast relatively high volume of plasma collection, altogether accounting for 39.6% of total plasma collections in 2016.

BLOOD_副本.png

The report highlights the following:
20120114.gifAnalysis on development of China blood product industry, including status quo, policy environment, market supply & demand, market size, market structure and competition pattern;
20120114.gifAnalysis on 8 market segments of China blood product industry, including development status, competition pattern and trends;
20120114.gifAnalysis on 13 major enterprises, including operation, blood product business, etc.;
Summary & forecast and trends.

1 Overview of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2 Development of China Blood Product Industry
2.1 Status Quo
2.2 Policy Environment
2.3 Market Supply and Demand
2.3.1 Supply
2.3.2 Demand
2.4 Market Size
2.5 Market Structure
2.6 Competition Pattern

3 Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Competition Pattern
3.2.3 Prospects
3.3 Blood Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Competition Pattern
3.8 Human Rabies Immunoglobulin  
3.8.1 Development Status
3.8.2 Competition Pattern

4 Major Enterprises
4.1 China Biologic Products, Inc. (NASDAQ: CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Development and Forecast
4.2 Hualan Biological Engineering,Inc.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Customer
4.2.7 Blood Product Business
4.2.8 Development and Forecast
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Customer
4.3.7 Blood Product Business
4.3.8 Development and Forecast
4.4 Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO)
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D and Investment
4.4.6 Customer
4.4.7 Blood Product Business
4.4.8 Development and Forecast
4.5 Zhenxing Biopharmaceutical & Chemical Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Customer
4.5.6 R&D and Investment
4.5.7 Blood Product Business
4.5.8 Development and Forecast
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Customer
4.6.7 Blood Product Business
4.6.8 Development and Forecast
4.7 Humanwell Healthcare Group Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D and Investment
4.7.6 Blood Product Business
4.7.7 Development and Forecast
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.8.1 Profile
4.8.2 Blood Product Business
4.9 Shanghai Institute of Biological Products Co., Ltd.
4.9.1 Profile
4.9.2 Blood Product Business
4.10 Shanxi Kangbao Biological Product Co., Ltd.
4.10.1 Profile
4.10.2 Blood Product Business
4.11 Green Cross China
4.11.1 Profile
4.11.2 Blood Product Business
4.12 Walvax Biotechnology Co, Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Product Business
4.13 Shenzhen Weiguang Biological Products Co., Ltd.
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Customer
4.13.6 R&D and Investment
4.13.7 Blood Product Business

5 Summary and Forecast
5.1 Summary and Forecast
5.2 Trends
5.2.1 Policies Encourage Industrial Development
5.2.2 Industrial Consolidation Accelerates, Concentration Further Enhances
5.2.3 Demand-Supply Gap and Product Consumption Structure Improvement are Beneficial to Industrial Development
5.2.4 Plasma Collection Volume and Number of Plasma Stations Determine Position in Industry
5.2.5 Comprehensive Utilization of Plasma Increases
Basic Components of Blood
Separation Procedure of Plasma Proteins
Classification and Function of Blood Products
Comparison of Gene Recombinant Blood Products and Traditional Blood Products
Types and Comparison of Domestic and Foreign Blood Products 
Blood Product Industry Chain
Time Consumption of Plasma Collection and Separation Process
Comparison of Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
Production & Sales Cycle of Blood Products
Development History of China Blood Product Industry
Lot Release Volume of Major Blood Products in China, 2014-2016
Main Policies on China Blood Product Industry, 1989-2016
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Occident
Plasma Collection in China vs. USA
Public Acceptance of Plasma Donation in China vs. USA, 2015
Plasma Collection Volume and YoY Growth Rate in China, 2008-2016
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2016
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2016 
Plasma Supply and Demand in China, 2015-2025E
Blood Product Price Changes in China
Market Size of China Blood Product Industry, 2010-2016
Blood Product Structure in China (by Lot Release Volume), 2014-2016
Number of Plasma Stations and Production-use Plasma Volume of Major Blood Product Enterprises in China, 2016
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2016
Net Income of Major Blood Product Enterprises in China, 2013-2016
R&D Expenditures of Major Blood Product Enterprises in China, 2013-2016
Comparison of Blood Product Revenue between Major Blood Product Enterprises in China, 2013-2016
Market Share of China Blood Product Industry (by Enterprise), 2016
Market Share of China Blood Product Industry (by Enterprise), 2015
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2016
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2016
Market Share of Human Albumin in China (by Lot Release Volume), 2016
Human Albumin Sales of Major Human Albumin Enterprises in China, 2013-2016
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2016
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2016
Human Immunoglobulin (pH4) for Intravenous Injection Sales of Major Human Immunoglobulin (pH4) for Intravenous Injection Enterprises in China, 2013-2016
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2016
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2016 
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2016
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2016
Lot Release Volume of Human Immunoglobulin in China, 2010-2016
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2016
Lot Release Volume of Human Prothrombin Complex in China, 2010-2016
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2016
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2016
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2016
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2016
Lot Release Volume of Rabies Vaccine in China, 2010-2016
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2016
Product Line of CBPO
Ownership Structure of CBPO, 2016
Revenue and Operating Income of CBPO, 2011-2016
Lot Release Volume of Blood Products of CBPO, 2015-2016
Revenue Breakdown of CBPO (by Product), 2011-2016
Revenue Structure of CBPO (by Product), 2011-2016
Market Share of CBPO (by Product), 2016
Gross Margin of CBPO, 2011-2016
R&D Costs and % of Total Revenue of CBPO, 2011-2016
CBPO’s Products under Research and R&D Process by the end of 2016
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Mar 2017
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Mar 2017
Ownership Structure of Xi'an Huitian Blood Products
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2014
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of Mar 2017
Revenue and Net Income of CBPO, 2016-2021E
Revenue and Net Income of Hualan Biological Engineering, 2013-2016
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2016
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2016
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2016
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2016
Hualan Biological Engineering’s Sales from Top 5 Customers and % of Total Sales, 2013-2016
Category and Specification of Blood Products of Hualan Biological Engineering
Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2013-2016
Revenue of Blood Products of Hualan Biological Engineering, 2013-2016
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2016
Revenue and Net Income of Hualan Biological Engineering, 2016-2021E
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2016
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2016
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2016
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2016
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2016
R&D Costs of Shanghai RAAS Blood Products, 2013-2016
Shanghai RAAS Blood Products’ Sales from Top 5 Customers and % of Total Sales, 2013-2016
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2013-2016
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products, 2015-2016
Revenue and Net Income of Shanghai RAAS Blood Products, 2016-2021E
Revenue and Net Income of TIANTANBIO, 2013-2016
Revenue Breakdown of TIANTANBIO (by Product), 2013-2016
Revenue Structure of TIANTANBIO (by Product), 2013-2016
Revenue Breakdown of TIANTANBIO (by Region), 2013-2016
Revenue Structure of TIANTANBIO (by Region), 2013-2016
Gross Margin of TIANTANBIO (by Product), 2013-2016
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2016
Basic Situation of Major R&D Projects of TIANTANBIO by the End of 2015
TIANTANBIO’s Sales from Top 5 Customers and % of Total Revenue, 2012-2015
Main Plasma Collection Stations of Chengdu Rongsheng Pharmaceuticals as of Mar 2017
Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2016
Revenue and Net Income of TIANTANBIO, 2016-2021E
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2013-2016
Revenue Breakdown of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2016
Revenue Structure of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2016
Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2013-2016
Zhenxing Biopharmaceutical & Chemical’s Sales from Top 5 Customers, 2013-2015
R&D Progress of Projects of Zhenxing Biopharmaceutical & Chemical by the End of 2015
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical & Chemical, 2013-2016
Use of Funds Raised by Zhenxing Biopharmaceutical & Chemical through Private Issuing of A Shares, 2016
Distribution of Plasma Collection Stations of Guangdong Shuanglin Bio-Pharmacy as of Mar 2017
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2010-2016
Output, Sales Volume and Inventory of Blood Products of Zhenxing Biopharmaceutical & Chemical, 2013-2015
Lot Release Volume of Blood Products of Zhenxing Biopharmaceutical & Chemical, 2015-2016
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2016-2021E
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2016
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Product), 2015-2016
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Region), 2015-2016
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
Gross Margin of Main Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2016
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2016
New Patents of Jiangxi Boya Bio-Pharmaceutical, 2017
Jiangxi Boya Bio-Pharmaceutical’s Sales from Top 5 Customers, 2013-2016
Jiangxi Boya Bio-Pharmaceutical’s Sales from Blood Products and % of Total Revenue, 2013-2016
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2016
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2016-2021E
Revenue and Net Income of Humanwell Healthcare Group, 2013-2016
Revenue Breakdown of Humanwell Healthcare Group (by Product), 2014-2016
Revenue Structure of Humanwell Healthcare Group (by Product), 2014-2016
Gross Margin of Humanwell Healthcare Group (by Product), 2014-2016
R&D Costs and % of Total Revenue of Humanwell Healthcare Group, 2013-2016
Humanwell Healthcare Group’s Revenue from Blood Products and % of Total Revenue, 2014-2016
Financial Data of Wuhan Zhongyuan Ruide Biological Products, 2014-2016
Revenue and Net Income of Humanwell Healthcare Group, 2016-2021E
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Distribution of Plasma Stations of Sichuan Yuanda Shuyang Pharmaceutical as of Mar 2017
Distribution of Plasma Collection Stations of Shanghai Institute of Biological Products as of Mar 2017
Specification of Main Blood Products of Shanghai Institute of Biological Products
Main Plasma Collection Stations of Shanxi Kangbao Biological Product as of Mar 2017
Distribution of Plasma Collection Stations of Green Cross China as of Mar 2017
Specification of Main Blood Products of Green Cross China
Revenue and Total Profit of Walvax Biotechnology, 2013-2016
Financial Indicators of Hebei Da'an Pharmaceutical, 2015-2016
Main Plasma Collection Stations of Hebei Da'an Pharmaceutical as of Mar 2017
Financial Indicators of Guangdong Weilun Biological Pharmaceutical, 2016
Distribution of Plasma Collection Stations of Guangdong Weilun Biological Pharmaceutical as of Mar 2017
Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2012-2015
Capacity, Output and Sales Volume of Shenzhen Weiguang Biological Products (by Product), 2012-2015
Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (unit: RMB mln)
Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2012-2015
Name List and Revenue Contribution of Shenzhen Weiguang Biological Products’ Top 5 Customers, 2012-2015
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2012-2015
Shenzhen Weiguang Biological Products’ Products under Research and R&D Process by the end of 2015
Fundraising Projects of Shenzhen Weiguang Biological Products
Distribution of Plasma Collection Stations of Shenzhen Weiguang Biological Products as of Mar 2017
Main Products of Shenzhen Weiguang Biological Products
Specification of Blood Products of Shenzhen Weiguang Biological Products
Plasma Collection Volume and Production-use Plasma Volume of Shenzhen Weiguang Biological Products, 2012-2015
Market Size of China Blood Product Industry, 2016-2021E
Merger & Acquisition Cases of Foreign Blood Product Giants
Merger & Acquisition Cases of China Blood Product Industry, 2008-2016

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Monoclonal Antibody Industry Report, 2013-2017

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the m...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Chemical Pharmaceutical Industry Report, 2011

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last yea...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统